Elevated endogenous cannabinoids in schizophrenia

NeuroReport

Volumn 10, Issue 8, 1999, Pages 1665-1669

  Leweke, F M ^a,d   Giuffrida, A ^c   Wurster, U ^b   Emrich, H M ^a   Piomelli, D ^c  

^a Dept of Clin Psychiat/Psychother ^*  (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

2 arachidonylglycerol; Anandamide; Cannabinoid receptors; Cerebrospinal fluid; Gas chromatography mass spectrometry; Palmitylethanolamide

Indexed keywords

ALCOHOL; ANANDAMIDE; BENZODIAZEPINE; CANNABINOID; CANNABIS; DIAZEPAM; LORAZEPAM; NEUROLEPTIC AGENT; OXAZEPAM; PALMIDROL; PERAZINE; RISPERIDONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANNABIS ADDICTION; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 0033519542     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199906030-00008     Document Type: Article

References (31)

1. 1. Kane JM. New Engl J Med 334, 34-41 (1996).
2. 2. Egan MF and Weinberger DR. Curr Opin Neurobiol 7, 701-707 (1997).
3. 3. Abood ME and Martin BR. Trends Pharmacol Sci 13, 201-206 (1992).
4. 4. Kovasznay B, Fleisher J, Tanenberg-Karant M et al. Schizophrenia Bull 23, 195-201 (1997).
5. 5. Andréasson S, Allebeck P, Engström A et al. Lancet 2, 1483-1486 (1987).
6. 6. Linszen DH, Dingemans PM and Lenior ME. Arch Gen Psychiatry 51, 273-279 (1994).
7. 7. Glass M, Dragunow M and Faull RLM. Neuroscience 77, 299-318 (1997).
8. 8. Emrich HM, Leweke FM and Schneider U. Pharmacol Biochem Behav 56, 803-807 (1997).
9. 9. Leweke FM, Schneider U, Thies M et al. Psycopharmacology 142, 230-235 (1999).
10. 10. Devane W, Hanus L, Breuer A et al. Science 258, 1946-1949 (1992).
11. 11. Di Marzo V, Fontana A, Cadas H et al. Nature 372, 686-691 (1994).
12. 12. Giuffrida A, Parsons LH, Kerr TM et al. Nature Neurosci 2, 358-363 (1999).
13. 13. Sugiura T, Kondo S, Sukagawa A et al. Biochem Biophys Res Commun 215, 89-97 (1995).
14. 14. Mechoulam R, Ben-Shabat S, Hanus L et al. Biochem Pharmacol 50, 83-90 (1995).
15. 15. Stella N, Schweitzer P and Piomelli D. Nature 388, 773-778 (1997).
16. 16. Calignano A, La Rana G, Giuffrida A et al. Nature 394, 277-281 (1998).
17. 17. American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn (DSM-IV). Washington DC: American Psychiatric Press Inc, 1994.
18. 18. Overall JE and Gorham DR. Psychol Rep 10, 799-812 (1962).
19. 19. Andersson M, Alvarez-Cermeno J, Bernardi G et al. J Neurol Neurosurg Psychiatry 57, 897-902 (1994).
20. 20. Giuffrida A and Piomelli D. FEBS Lett 422, 373-376 (1998).
21. 21. Giuffrida A and Piomelli D. Purification and high-resolution analysis of anandamide and other fatty acylethanolamides. In: Laychock SG and Rubin RP, eds. Lipid Second Messengers, Boca Raton, London, New York, Washington, D.C.; CRC Press LLC, 1998; 113-133.
22. 22 Sedvall G and Farde L. Lancet 346, 743-749 (1995).
23. 23 Skaper SD, Buriani A, Dal Toso R et al. Proc Natl Acad Sci USA 93, 3984-3989 (1996).
24. 24 Schmid PC, Krebsbach RJ, Perry SR et al. FEBS Lett 375, 117-120 (1995).
25. 25 Bazan NG. Biochim Biophys Acta 218, 1-10 (1970).
26. 26 Desamaud F, Cadas H and Piomelli D. J Biol Chem 270, 6030-6035 (1995).
27. 27. Cravatt BF, Giang DK, Mayfield SP et al. Nature 384, 83-87 (1996).
28. 28 Beltramo M, Stella N, Calignano A et al. Science 277, 1094-1097 (1997).
29. 29 Wagner JA, Varga K and Kunos G. J Mol Med 76, 824-836 (1998).
30. 30 Sugiura T, Kodaka T, Nakane S et al. Biochem Biophys Res Commun 243, 838-843 (1998).
31. 31 Mechoulam R, Fride E, Ben-Shabat S et al. Eur J Pharmacol 362, R1-R3 (1998).